The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

Novo Nordisk markets a semaglutide pill to treat diabetes, but despite technology that improves absorption in the gut, it doesn’t match the efficacy of the injectables. In contrast, small ...

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

A Fremont business owner was arrested on March 12 and charged with prescribing prescription drugs without a license and ...

Stanford Medicine researchers have identified a promising, naturally occurring molecule that could help people lose ...

Analysts expect the pill to be as effective, safe and tolerable to take as Novo Nordisk's semaglutide – the active ingredient in its popular but costly weight loss injection Wegovy and diabetes ...